Frontiers in Pharmacology (Apr 2023)
Current understanding of genetic associations with delayed hypersensitivity reactions induced by antibiotics and anti-osteoporotic drugs
- Chih-Hsuan Wung,
- Chuang-Wei Wang,
- Chuang-Wei Wang,
- Chuang-Wei Wang,
- Chuang-Wei Wang,
- Kuo-Chu Lai,
- Kuo-Chu Lai,
- Kuo-Chu Lai,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Wei-Ti Chen,
- Wei-Ti Chen,
- Wei-Ti Chen,
- Shuen-Iu Hung,
- Shuen-Iu Hung,
- Shuen-Iu Hung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Taiwan Severe Cutaneous Adverse Reaction Consortium
Affiliations
- Chih-Hsuan Wung
- Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Chuang-Wei Wang
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei and Keelung, Taiwan
- Chuang-Wei Wang
- Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Chuang-Wei Wang
- Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
- Chuang-Wei Wang
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Kuo-Chu Lai
- Department of Physiology and Pharmacology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Kuo-Chu Lai
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Kuo-Chu Lai
- Division of Hematology and Oncology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City, Taiwan
- Chun-Bing Chen
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei and Keelung, Taiwan
- Chun-Bing Chen
- Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Chun-Bing Chen
- Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
- Chun-Bing Chen
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Chun-Bing Chen
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Chun-Bing Chen
- 0Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan
- Chun-Bing Chen
- 1Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chun-Bing Chen
- 2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Wei-Ti Chen
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei and Keelung, Taiwan
- Wei-Ti Chen
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Wei-Ti Chen
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Shuen-Iu Hung
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei and Keelung, Taiwan
- Shuen-Iu Hung
- Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Shuen-Iu Hung
- 3Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
- Wen-Hung Chung
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei and Keelung, Taiwan
- Wen-Hung Chung
- Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Wen-Hung Chung
- Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
- Wen-Hung Chung
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Wen-Hung Chung
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Wen-Hung Chung
- 0Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan
- Wen-Hung Chung
- 1Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan
- Wen-Hung Chung
- 2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Wen-Hung Chung
- 4Department of Dermatology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China
- Wen-Hung Chung
- 5Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- Wen-Hung Chung
- 6Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan
- Taiwan Severe Cutaneous Adverse Reaction Consortium
- DOI
- https://doi.org/10.3389/fphar.2023.1183491
- Journal volume & issue
-
Vol. 14
Abstract
Drug-induced delayed hypersensitivity reactions (DHRs) is still a clinical and healthcare burden in every country. Increasing reports of DHRs have caught our attention to explore the genetic relationship, especially life-threatening severe cutaneous adverse drug reactions (SCARs), including acute generalized exanthematous pustulosis (AGEP), drug reactions with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). In recent years, many studies have investigated the immune mechanism and genetic markers of DHRs. Besides, several studies have stated the associations between antibiotics-as well as anti-osteoporotic drugs (AOD)-induced SCARs and specific human leukocyte antigens (HLA) alleles. Strong associations between drugs and HLA alleles such as co-trimoxazole-induced DRESS and HLA-B*13:01 (Odds ratio (OR) = 45), dapsone-DRESS and HLA-B*13:01 (OR = 122.1), vancomycin-DRESS and HLA-A*32:01 (OR = 403), clindamycin-DHRs and HLA-B*15:27 (OR = 55.6), and strontium ranelate (SR)-SJS/TEN and HLA-A*33:03 (OR = 25.97) are listed. We summarized the immune mechanism of SCARs, update the latest knowledge of pharmacogenomics of antibiotics- and AOD-induced SCARs, and indicate the potential clinical use of these genetic markers for SCARs prevention in this mini review article.
Keywords
- delayed hypersensitivity reactions
- human leukocyte antigens
- Stevens-Johnson syndrome
- toxic epidermal necrosis
- drug reactions with eosinophilia and systemic symptoms
